SPRY Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
37.7M
+12.0%
33.7M
+48.4%
22.7M
-19.2%
28.1M
-13.6%
32.5M
Cost of Revenue
10.1M
-21.4%
12.8M
+104.4%
6.3M
+2.1%
6.2M
-24.9%
8.2M
Gross Profit
27.6M
+32.7%
20.8M
+26.9%
16.4M
-25.2%
21.9M
-9.8%
24.3M
Operating Expenses
61.8M
-24.9%
82.3M
+7.5%
76.5M
+20.7%
63.4M
-18.2%
77.5M
R&D
18.3M
+288.7%
4.7M
+8.3%
4.3M
+25.9%
3.4M
+25.2%
2.8M
SG&A
43.5M
-43.9%
77.6M
+7.4%
72.2M
+20.4%
60.0M
-19.8%
74.8M
Operating Income
-34171000
+44.4%
-61465000
-2.2%
-60145000
-45.1%
-41465000
+22.0%
-53192000
EBITDA
-33756000
+44.7%
-61049000
-2.2%
-59748000
-45.6%
-41048000
+22.3%
-52801000
Net Income
-35587000
+42.9%
-62339000
-2.8%
-60618000
-47.5%
-41097000
+19.7%
-51151000
EPS (Basic)
$-0.36
+42.9%
$-0.63
-3.3%
$-0.61
-48.8%
$-0.41
+21.2%
$-0.52
EPS (Diluted)
$-0.36
+42.9%
$-0.63
-3.3%
$-0.61
-48.8%
$-0.41
+21.2%
$-0.52
Shares (Diluted)
99.7M
+0.4%
99.3M
+0.0%
99.3M
+0.3%
99.0M
+0.2%
98.8M
ARS Pharmaceuticals (SPRY) — Financials